AU2009324251A1 - Fully human influenza M2 specific antibodies - Google Patents

Fully human influenza M2 specific antibodies Download PDF

Info

Publication number
AU2009324251A1
AU2009324251A1 AU2009324251A AU2009324251A AU2009324251A1 AU 2009324251 A1 AU2009324251 A1 AU 2009324251A1 AU 2009324251 A AU2009324251 A AU 2009324251A AU 2009324251 A AU2009324251 A AU 2009324251A AU 2009324251 A1 AU2009324251 A1 AU 2009324251A1
Authority
AU
Australia
Prior art keywords
seq
peptide
monoclonal antibody
influenza
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009324251A
Other languages
English (en)
Inventor
Martin Bachmann
Monika Bauer
Roger Beerli
Nicole Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elatos GmbH
Original Assignee
Elatos GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elatos GmbH filed Critical Elatos GmbH
Publication of AU2009324251A1 publication Critical patent/AU2009324251A1/en
Assigned to ELATOS GMBH reassignment ELATOS GMBH Request for Assignment Assignors: INTERCELL AG
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2009324251A 2008-12-04 2009-11-30 Fully human influenza M2 specific antibodies Abandoned AU2009324251A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08170749 2008-12-04
EP08170749.9 2008-12-04
EP09173548 2009-10-20
EP09173548.0 2009-10-20
PCT/EP2009/066052 WO2010063675A1 (en) 2008-12-04 2009-11-30 Fully human influenza m2 specific antibodies

Publications (1)

Publication Number Publication Date
AU2009324251A1 true AU2009324251A1 (en) 2010-06-10

Family

ID=42232909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324251A Abandoned AU2009324251A1 (en) 2008-12-04 2009-11-30 Fully human influenza M2 specific antibodies

Country Status (7)

Country Link
US (2) US8460670B2 (https=)
EP (1) EP2365827A1 (https=)
JP (1) JP2012510802A (https=)
CN (1) CN102238963A (https=)
AU (1) AU2009324251A1 (https=)
CA (1) CA2745598A1 (https=)
WO (1) WO2010063675A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies
EP2432803A2 (en) * 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012112489A2 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
CA2478973A1 (en) * 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20050170334A1 (en) 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US8003106B2 (en) 2002-03-13 2011-08-23 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP1819732A2 (en) * 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies

Also Published As

Publication number Publication date
US20110268740A1 (en) 2011-11-03
WO2010063675A1 (en) 2010-06-10
EP2365827A1 (en) 2011-09-21
US8460670B2 (en) 2013-06-11
US20130109845A1 (en) 2013-05-02
JP2012510802A (ja) 2012-05-17
CA2745598A1 (en) 2010-06-10
CN102238963A (zh) 2011-11-09

Similar Documents

Publication Publication Date Title
US11136379B2 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
AU2012205663B2 (en) Antibodies directed against influenza
AU2011282423B2 (en) Cross-protective pathogen protection, methods and compositions thereof
KR102668588B1 (ko) 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
EP2793945B1 (en) Antibodies useful in passive influenza immunization
RU2721706C2 (ru) Нейтрализующие связывающие молекулы, направленные против вируса гриппа, и пути их применения
CN106243218B (zh) 抗Flu B的广谱单克隆抗体及其用途
US8460670B2 (en) Fully human influenza M2 specific antibodies
US12509503B2 (en) Pan-neuraminidase inhibiting antibodies
US20210002354A1 (en) Methods and composition for neutralization of influenza
Paul Characterization and Optimization of Interaction of Monoclonal Antibodies With Influenza a Hemagglutinin
HK1203410B (en) Antibodies useful in passive influenza immunization
HK1250725B (zh) 中和抗流感结合分子及其用途
NZ626716B2 (en) Antibodies useful in passive influenza immunization

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ELATOS GMBH

Free format text: FORMER APPLICANT(S): INTERCELL AG

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application